OncoMed press release

OncoMed Pharmaceuticals press release, November 4, 2008 [PDF]. Excerpt:

OncoMed's lead anti-cancer stem cell antibody, OMP-21M18, entered human clinical studies earlier this year with the initiation of a Phase I trial in patients with advanced solid tumors. OMP-21M18 targets a major cancer stem cell pathway, and is a part of OncoMed's collaboration with GlaxoSmithKline. The Phase I clinical trial is designed to evaluate the safety of escalating doses of OMP-21M18 in patients with solid tumors who have received previous treatment. Pharmacokinetics and initial indications of efficacy will also be assessed. OMP-21M18 is the first anti-cancer stem cell antibody against this novel target critical to cancer stem cells growth and development.

For news items about this press release, see, for example: "OncoMed Pharmaceuticals Completes Series B Financing: Lead Cancer Stem Cell Product Candidate Enters Clinical Trials", November 4, 2008 in Yahoo! Finance and The Earth Times. See also: OncoMed raises $93M in add-on funding, Lisa Sibley, Silicon Valley/San Jose Business Journal, November 4, 2008.